EP2900832A4 - Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption - Google Patents

Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption

Info

Publication number
EP2900832A4
EP2900832A4 EP13840221.9A EP13840221A EP2900832A4 EP 2900832 A4 EP2900832 A4 EP 2900832A4 EP 13840221 A EP13840221 A EP 13840221A EP 2900832 A4 EP2900832 A4 EP 2900832A4
Authority
EP
European Patent Office
Prior art keywords
administered
drug
patient
methods
determining whether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13840221.9A
Other languages
German (de)
French (fr)
Other versions
EP2900832A1 (en
Inventor
Ernst J Schaefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Heart Diagnostics Corp
Original Assignee
Boston Heart Diagnostics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Heart Diagnostics Corp filed Critical Boston Heart Diagnostics Corp
Publication of EP2900832A1 publication Critical patent/EP2900832A1/en
Publication of EP2900832A4 publication Critical patent/EP2900832A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP13840221.9A 2012-09-27 2013-09-27 Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption Withdrawn EP2900832A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706638P 2012-09-27 2012-09-27
US13/950,732 US20140088073A1 (en) 2012-09-27 2013-07-25 Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption
PCT/US2013/062241 WO2014052790A1 (en) 2012-09-27 2013-09-27 Methods for determining whether a patient should be administered a drug that inhibits cholesterol absortion

Publications (2)

Publication Number Publication Date
EP2900832A1 EP2900832A1 (en) 2015-08-05
EP2900832A4 true EP2900832A4 (en) 2016-05-18

Family

ID=50339462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13840221.9A Withdrawn EP2900832A4 (en) 2012-09-27 2013-09-27 Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption

Country Status (5)

Country Link
US (1) US20140088073A1 (en)
EP (1) EP2900832A4 (en)
AU (1) AU2013323271A1 (en)
CA (1) CA2886400A1 (en)
WO (1) WO2014052790A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197242A1 (en) * 2006-04-24 2009-08-06 Kaddurah-Daouk Rima F Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
WO2009002873A1 (en) * 2007-06-22 2008-12-31 Cvi Pharmaceuticals Limited Compounds, compositions and methods for reducing lipid levels
US20130312498A1 (en) * 2012-05-25 2013-11-28 Foundation For Health Improvement And Technology Cardiovascular disease risk assessment and treatment by sterol and/or stanol markers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197242A1 (en) * 2006-04-24 2009-08-06 Kaddurah-Daouk Rima F Lipidomic Approaches to Determining Drug Response Phenotypes in Cardiovascular Disease

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
G THOMPSON: "Why some patients respond poorly to statins and how this might be remedied", EUROPEAN HEART JOURNAL, vol. 23, no. 3, 1 February 2002 (2002-02-01), pages 200 - 206, XP055144374, ISSN: 0195-668X, DOI: 10.1053/euhj.2001.3071 *
HOENIG MR, WALKER PJ, GURNSEY C, BEADLE K, JOHNSON L: "Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin", J CARDIOVASC PHARMACOL, vol. 56, no. 4, October 2010 (2010-10-01), pages 396 - 401, XP008179623 *
L. JAKULJ ET AL: "Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial", JOURNAL OF LIPID RESEARCH, vol. 51, no. 4, 14 October 2009 (2009-10-14), US, pages 755 - 762, XP055261091, ISSN: 0022-2275, DOI: 10.1194/jlr.M001487 *
M. FARNIER ET AL: "Lipid-altering efficacy of ezetimibe/simvastatin 10/20?mg compared with rosuvastatin 10?mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol. 63, no. 4, 1 April 2009 (2009-04-01), GB, pages 547 - 559, XP055242075, ISSN: 1368-5031, DOI: 10.1111/j.1742-1241.2009.02022.x *
N. R. MATTHAN ET AL: "Alterations in cholesterol absorption/synthesis markers characterize Framingham Offspring Study participants with CHD", THE JOURNAL OF LIPID RESEARCH, vol. 50, no. 9, 1 September 2009 (2009-09-01), pages 1927 - 1935, XP055061446, ISSN: 0022-2275, DOI: 10.1194/jlr.P900039-JLR200 *
N. R. MATTHAN ET AL: "Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial", THE JOURNAL OF LIPID RESEARCH, vol. 51, no. 1, 3 July 2009 (2009-07-03), pages 202 - 209, XP055143952, ISSN: 0022-2275, DOI: 10.1194/jlr.M900032-JLR200 *
OKADA KOZO ET AL: "Measuring the Baseline Cholesterol Absorption and Synthesis Marker Can Predict the LDL-C Lowering Response to Ezetimibe-Statin Combination Therapy in Patients with Coronary Artery Disease: A Multi-Center Prospective Randomized Trial", BIOSIS,, 23 November 2010 (2010-11-23), XP002696327 *
OLIVIER S DESCAMPS ET AL: "Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today?", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 217, no. 2, 6 June 2011 (2011-06-06), pages 308 - 321, XP028247545, ISSN: 0021-9150, [retrieved on 20110612], DOI: 10.1016/J.ATHEROSCLEROSIS.2011.06.010 *
See also references of WO2014052790A1 *
T. A. MIETTINEN ET AL: "Noncholesterol Sterols and Cholesterol Lowering by Long-Term Simvastatin Treatment in Coronary Patients : Relation to Basal Serum Cholestanol", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, vol. 20, no. 5, 1 May 2000 (2000-05-01), pages 1340 - 1346, XP055144021, ISSN: 1079-5642, DOI: 10.1161/01.ATV.20.5.1340 *
T. M. VAN HIMBERGEN ET AL: "Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers", THE JOURNAL OF LIPID RESEARCH, vol. 50, no. 4, 1 January 2008 (2008-01-01), pages 730 - 739, XP055061470, ISSN: 0022-2275, DOI: 10.1194/jlr.P800042-JLR200 *

Also Published As

Publication number Publication date
CA2886400A1 (en) 2014-04-03
AU2013323271A1 (en) 2015-04-16
EP2900832A1 (en) 2015-08-05
WO2014052790A1 (en) 2014-04-03
US20140088073A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
HK1213503A1 (en) Drug delivery medical device
HK1198139A1 (en) Drug delivery medical device
SG11201403452RA (en) Systems and methods for determining insulin therapy for a patient
AP2013007178A0 (en) BCMA-based stratification and therapy for multiplemyeloma patients
HK1208801A1 (en) Orally administered medical composition
GB201218307D0 (en) Patient monitor
IL228709A0 (en) Unit dose form for oral administration
EP2560624A4 (en) Therapeutic formulation for reduced drug side effects
ZA201404655B (en) Methods for improving medical therapies
IL237138B (en) Pirfenidone for use as a medicament administered in calculated dosages
GB201400746D0 (en) Aripiprazole medicament formulation and preparation method therefor
HK1206292A1 (en) Medicament administration
IL232946A0 (en) Inhalable medicament comprising tiotropium
HK1201209A1 (en) Therapeutic agent for diabetes
ZA201405797B (en) Pharmaceutical dosage form
AP2015008208A0 (en) Pharmaceutical administration forms comprising
EP2777683A4 (en) Storage case for pharmaceutical preparation syringe unit
EP2898912A4 (en) Drug administration instrument
EP2870971A4 (en) Drug for preventing/treating ocular disease
EP2548580A4 (en) Pharmaceutical for pseudo-exercise therapy
EP2900832A4 (en) Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption
ZA201502354B (en) Pharmaceutical dosage form
AU347721S (en) Cassette device for administering medication
AU2012902957A0 (en) Bed Patient Monitor
GB201113172D0 (en) Medical blister

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160419

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/92 20060101ALI20160413BHEP

Ipc: G01N 33/50 20060101ALI20160413BHEP

Ipc: C12Q 1/60 20060101AFI20160413BHEP

R17P Request for examination filed (corrected)

Effective date: 20150420

17Q First examination report despatched

Effective date: 20170927

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20181030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190312